{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:33:46Z","timestamp":1791351226564,"version":"4.3.1"},"reference-count":201,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Slovene Research Agency","award":["P1-0140"],"award-info":[{"award-number":["P1-0140"]}]},{"name":"Slovene Research Agency","award":["N1-0022"],"award-info":[{"award-number":["N1-0022"]}]},{"name":"Slovene Research Agency","award":["J1-6739"],"award-info":[{"award-number":["J1-6739"]}]},{"name":"Slovene Research Agency","award":["P1-0048"],"award-info":[{"award-number":["P1-0048"]}]},{"name":"COST Action PROTEOSTASIS","award":["BM1307"],"award-info":[{"award-number":["BM1307"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","cell.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.tips.2017.06.003","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T23:03:44Z","timestamp":1498691024000},"page":"873-898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":185,"title":["The Future of Cysteine Cathepsins in Disease Management"],"prefix":"10.1016","volume":"38","author":[{"given":"Lovro","family":"Kramer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Du\u0161an","family":"Turk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Turk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2017.06.003_bib0005","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/nrd2092","article-title":"Targeting proteases: successes, failures and future prospects","volume":"5","author":"Turk","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2017.06.003_bib0010","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/nrd3053","article-title":"Emerging principles in protease-based drug discovery","volume":"9","author":"Drag","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2017.06.003_bib0015","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/emboj.2012.42","article-title":"Protease signalling: the cutting edge","volume":"31","author":"Turk","year":"2012","journal-title":"EMBO J."},{"key":"10.1016\/j.tips.2017.06.003_bib0020","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1172\/JCI42918","article-title":"Specialized roles for cysteine cathepsins in health and disease","volume":"120","author":"Reiser","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2017.06.003_bib0025","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2174\/138161207780162962","article-title":"Emerging roles of cysteine cathepsins in disease and their potential as drug targets","volume":"13","author":"Vasiljeva","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.tips.2017.06.003_bib0030","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1128\/MCB.26.6.2309-2316.2006","article-title":"Murine cathepsin F deficiency causes neuronal lipofuscinosis and late-onset neurological disease","volume":"26","author":"Tang","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.tips.2017.06.003_bib0035","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/hmg\/dds558","article-title":"Cathepsin F mutations cause type B Kufs disease, an adult-onset neuronal ceroid lipofuscinosis","volume":"22","author":"Smith","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tips.2017.06.003_bib0040","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.arr.2016.04.010","article-title":"Lysosomal cathepsins and their regulation in aging and neurodegeneration","volume":"32","author":"Stoka","year":"2016","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.tips.2017.06.003_bib0045","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1016\/j.bbagen.2014.03.017","article-title":"Cysteine cathepsins and extracellular matrix degradation","volume":"1840","author":"Fonovi\u0107","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.tips.2017.06.003_bib0050","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbapap.2011.10.002","article-title":"Cysteine cathepsins: from structure, function and regulation to new frontiers","volume":"1824","author":"Turk","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.tips.2017.06.003_bib0055","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1074-7613(00)80021-7","article-title":"Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice","volume":"10","author":"Nakagawa","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.tips.2017.06.003_bib0060","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1074-7613(00)80020-5","article-title":"Cathepsin S required for normal MHC class II peptide loading and germinal center development","volume":"10","author":"Shi","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.tips.2017.06.003_bib0065","doi-asserted-by":"crossref","first-page":"13453","DOI":"10.1073\/pnas.95.23.13453","article-title":"Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice","volume":"95","author":"Saftig","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2017.06.003_bib0070","doi-asserted-by":"crossref","first-page":"12517","DOI":"10.1074\/jbc.271.21.12517","article-title":"Proteolytic activity of human osteoclast cathepsin K expression, purification, activation, and substrate identification","volume":"271","author":"Bossard","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0075","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nrc4027","article-title":"Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response","volume":"15","author":"Olson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tips.2017.06.003_bib0080","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/17460441.2016.1160884","article-title":"Cathepsin K osteoporosis trials, pycnodysostosis and mouse deficiency models: commonalities and differences","volume":"11","author":"Br\u00f6mme","year":"2016","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.tips.2017.06.003_bib0085","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.pharmthera.2011.04.010","article-title":"Cysteinyl cathepsins and mast cell proteases in the pathogenesis and therapeutics of cardiovascular diseases","volume":"131","author":"Qin","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.tips.2017.06.003_bib0090","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1515\/hsz-2016-0252","article-title":"Lysosomes in programmed cell death pathways: from initiators to amplifiers","volume":"398","author":"Kav\u010di\u010d","year":"2017","journal-title":"Biol. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0095","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-biochem-060713-035352","article-title":"Activity-based profiling of proteases","volume":"83","author":"Sanman","year":"2014","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.tips.2017.06.003_bib0100","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1146\/annurev-immunol-041015-055420","article-title":"Variations in MHC class II antigen processing and presentation in health and disease","volume":"34","author":"Unanue","year":"2016","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.tips.2017.06.003_bib0105","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1126\/science.280.5362.450","article-title":"Cathepsin L: critical role in Ii degradation and CD4T cell selection in the thymus","volume":"280","author":"Nakagawa","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.tips.2017.06.003_bib0110","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1172\/JCI200318028","article-title":"Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis","volume":"112","author":"Tolosa","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2017.06.003_bib0115","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jaut.2012.02.003","article-title":"Cathepsin S dominates autoantigen processing in human thymic dendritic cells","volume":"38","author":"Stoeckle","year":"2012","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.tips.2017.06.003_bib0120","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nri2671","article-title":"Endolysosomal proteases and their inhibitors in immunity","volume":"9","author":"Bird","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tips.2017.06.003_bib0125","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.4049\/jimmunol.0901486","article-title":"Distinct protease requirements for antigen presentation in vitro and in vivo","volume":"184","author":"Matthews","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.tips.2017.06.003_bib0130","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1073\/pnas.1115091109","article-title":"Cleavage of Toll-like receptor 3 by cathepsins B and H is essential for signaling","volume":"109","author":"Garcia-Cattaneo","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2017.06.003_bib0135","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1126\/science.1150110","article-title":"Cathepsin K-dependent Toll-like receptor 9 signaling revealed in experimental arthritis","volume":"319","author":"Asagiri","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.tips.2017.06.003_bib0140","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1084\/jem.20100682","article-title":"Nucleic acid recognition by Toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase","volume":"208","author":"Ewald","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tips.2017.06.003_bib0145","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2119\/molmed.2015.00197","article-title":"The HIV protease inhibitor saquinavir inhibits HMGB1 driven inflammation by targeting the interaction of cathepsin V with TLR4\/MyD88","volume":"21","author":"Pribis","year":"2015","journal-title":"Mol. Med."},{"key":"10.1016\/j.tips.2017.06.003_bib0150","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1084\/jem.20151938","article-title":"Cathepsin B modulates lysosomal biogenesis and host defense against Francisella novicida infection","volume":"213","author":"Qi","year":"2016","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tips.2017.06.003_bib0155","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.1174447","article-title":"A gene network regulating lysosomal biogenesis and function","volume":"325","author":"Sardiello","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.tips.2017.06.003_bib0160","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1073\/pnas.95.8.4516","article-title":"Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation","volume":"95","author":"Deussing","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2017.06.003_bib0165","doi-asserted-by":"crossref","first-page":"e3194","DOI":"10.1371\/journal.pntd.0003194","article-title":"Cathepsin B in antigen-presenting cells controls mediators of the Th1 immune response during Leishmania major infection","volume":"8","author":"Gonzalez-Leal","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.tips.2017.06.003_bib0170","doi-asserted-by":"crossref","first-page":"690","DOI":"10.4049\/jimmunol.181.1.690","article-title":"Cathepsin B is involved in the trafficking of TNF-alpha-containing vesicles to the plasma membrane in macrophages","volume":"181","author":"Ha","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.tips.2017.06.003_bib0175","doi-asserted-by":"crossref","first-page":"8627","DOI":"10.1073\/pnas.96.15.8627","article-title":"Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo","volume":"96","author":"Pham","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2017.06.003_bib0180","doi-asserted-by":"crossref","first-page":"18551","DOI":"10.1074\/jbc.M100223200","article-title":"Dipeptidyl peptidase I is essential for activation of mast cell chymases, but not tryptases, in mice","volume":"276","author":"Wolters","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0185","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1172\/JCI0213462","article-title":"Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis","volume":"109","author":"Adkison","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2017.06.003_bib0190","doi-asserted-by":"crossref","first-page":"20514","DOI":"10.1074\/jbc.M109.094573","article-title":"Cathepsin H is an additional convertase of pro-granzyme B","volume":"285","author":"D\u2019Angelo","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0195","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1074\/mcp.M114.044628","article-title":"Proteomic identification of cysteine cathepsin substrates shed from the surface of cancer cells","volume":"14","author":"Soboti\u010d","year":"2015","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.tips.2017.06.003_bib0200","doi-asserted-by":"crossref","first-page":"13800","DOI":"10.1074\/jbc.M115.638395","article-title":"Cysteine cathepsins activate ELR chemokines and inactivate non-ELR chemokines","volume":"290","author":"Repnik","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0205","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1515\/hsz-2012-0283","article-title":"The proinflammatory cytokines interleukin-1alpha and tumor necrosis factor alpha promote the expression and secretion of proteolytically active cathepsin S from human chondrocytes","volume":"394","author":"Cagli\u010d","year":"2013","journal-title":"Biol. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0210","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1016\/j.celrep.2016.08.035","article-title":"STAT3 and STAT6 signaling pathways synergize to promote cathepsin secretion from macrophages via IRE1alpha activation","volume":"16","author":"Yan","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.tips.2017.06.003_bib0215","doi-asserted-by":"crossref","first-page":"33076","DOI":"10.1074\/jbc.M705761200","article-title":"Glycosaminoglycans facilitate procathepsin B activation through disruption of propeptide\u2013mature enzyme interactions","volume":"282","author":"Cagli\u010d","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0220","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1002\/jbmr.1701","article-title":"Protein kinase C-delta deficiency perturbs bone homeostasis by selective uncoupling of cathepsin K secretion and ruffled border formation in osteoclasts","volume":"27","author":"Cremasco","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tips.2017.06.003_bib0225","doi-asserted-by":"crossref","first-page":"32347","DOI":"10.1074\/jbc.273.48.32347","article-title":"The collagenolytic activity of cathepsin K is unique among mammalian proteinases","volume":"273","author":"Garnero","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0230","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.gene.2009.06.013","article-title":"Identification of NFAT binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand","volume":"446","author":"Balkan","year":"2009","journal-title":"Gene"},{"key":"10.1016\/j.tips.2017.06.003_bib0235","doi-asserted-by":"crossref","first-page":"17474","DOI":"10.1073\/pnas.1414126111","article-title":"Structural basis of collagen fiber degradation by cathepsin K","volume":"111","author":"Aguda","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2017.06.003_bib0240","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1517\/13543780902832661","article-title":"Cathepsin K inhibitors for osteoporosis and potential off-target effects","volume":"18","author":"Br\u00f6mme","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.tips.2017.06.003_bib0245","doi-asserted-by":"crossref","first-page":"5470","DOI":"10.1074\/jbc.M310349200","article-title":"Regulation of collagenase activities of human cathepsins by glycosaminoglycans","volume":"279","author":"Li","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0250","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/bph.13383","article-title":"A novel approach to inhibit bone resorption: exosite inhibitors against cathepsin K","volume":"173","author":"Panwar","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2017.06.003_bib0255","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2353\/ajpath.2008.070494","article-title":"Cleavage of type II collagen by cathepsin K in human osteoarthritic cartilage","volume":"173","author":"Dejica","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.tips.2017.06.003_bib0260","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1158\/1535-7163.MCT-14-0253","article-title":"Efficacy of a cathepsin K inhibitor in a preclinical model for prevention and treatment of breast cancer bone metastasis","volume":"13","author":"Duong","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tips.2017.06.003_bib0265","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/onc.2012.166","article-title":"Macrophage cathepsin K promotes prostate tumor progression in bone","volume":"32","author":"Herroon","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.tips.2017.06.003_bib0270","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1172\/JCI181","article-title":"Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells","volume":"102","author":"Sukhova","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2017.06.003_bib0275","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1161\/ATVBAHA.111.235002","article-title":"Cathepsin K deficiency reduces elastase perfusion-induced abdominal aortic aneurysms in mice","volume":"32","author":"Sun","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.tips.2017.06.003_bib0280","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/CIRCULATIONAHA.105.561449","article-title":"Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation","volume":"113","author":"Lutgens","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.tips.2017.06.003_bib0285","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nri3621","article-title":"Pathological pain and the neuroimmune interface","volume":"14","author":"Grace","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tips.2017.06.003_bib0290","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fncel.2013.00026","article-title":"Microglia, seen from the CX3CR1angle","volume":"7","author":"Wolf","year":"2013","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.tips.2017.06.003_bib0295","doi-asserted-by":"crossref","first-page":"10655","DOI":"10.1073\/pnas.0610811104","article-title":"Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain","volume":"104","author":"Clark","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2017.06.003_bib0300","doi-asserted-by":"crossref","first-page":"RC87","DOI":"10.1523\/JNEUROSCI.20-15-j0004.2000","article-title":"Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage","volume":"20","author":"Chapman","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2017.06.003_bib0305","doi-asserted-by":"crossref","first-page":"27215","DOI":"10.1074\/jbc.M114.599712","article-title":"Cathepsin S causes inflammatory pain via biased agonism of PAR2 and TRPV4","volume":"289","author":"Zhao","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0310","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1053\/j.gastro.2011.07.035","article-title":"Cathepsin S is activated during colitis and causes visceral hyperalgesia by a PAR2-dependent mechanism in mice","volume":"141","author":"Cattaruzza","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tips.2017.06.003_bib0315","doi-asserted-by":"crossref","first-page":"7864","DOI":"10.1038\/ncomms8864","article-title":"Redefining the concept of protease-activated receptors: cathepsin S evokes itch via activation of Mrgprs","volume":"6","author":"Reddy","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2017.06.003_bib0320","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/nm.4172","article-title":"Adenosine-to-inosine RNA editing controls cathepsin S expression in atherosclerosis by enabling HuR-mediated post-transcriptional regulation","volume":"22","author":"Stellos","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2017.06.003_bib0325","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1021\/ml500283g","article-title":"Discovery of cathepsin S inhibitor LY3000328 for the treatment of abdominal aortic aneurysm","volume":"5","author":"Jadhav","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.tips.2017.06.003_bib0330","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1161\/CIRCULATIONAHA.108.827972","article-title":"Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease","volume":"119","author":"Aikawa","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.tips.2017.06.003_bib0335","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.ajpath.2014.11.026","article-title":"Selective cathepsin S inhibition attenuates atherosclerosis in apolipoprotein E-deficient mice with chronic renal disease","volume":"185","author":"Figueiredo","year":"2015","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.tips.2017.06.003_bib0340","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1002\/art.34351","article-title":"Spinal cathepsin S and fractalkine contribute to chronic pain in the collagen-induced arthritis model","volume":"64","author":"Clark","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.tips.2017.06.003_bib0345","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/nrc1949","article-title":"Cysteine cathepsins: multifunctional enzymes in cancer","volume":"6","author":"Mohamed","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tips.2017.06.003_bib0350","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.semcancer.2015.08.001","article-title":"Lysosomal cysteine peptidases \u2212 molecules signaling tumor cell death and survival","volume":"35","author":"Pislar","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.tips.2017.06.003_bib0355","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1073\/pnas.0907240107","article-title":"Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice","volume":"107","author":"Sevenich","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2017.06.003_bib0360","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1101\/gad.1407406","article-title":"Distinct roles for cysteine cathepsin genes in multistage tumorigenesis","volume":"20","author":"Gocheva","year":"2006","journal-title":"Genes. Dev."},{"key":"10.1016\/j.tips.2017.06.003_bib0365","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1101\/gad.270439.115","article-title":"Combined deletion of cathepsin protease family members reveals compensatory mechanisms in cancer","volume":"30","author":"Akkari","year":"2016","journal-title":"Genes. Dev."},{"key":"10.1016\/j.tips.2017.06.003_bib0370","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1101\/gad.224899.113","article-title":"Cathepsin C is a tissue-specific regulator of squamous carcinogenesis","volume":"27","author":"Ruffell","year":"2013","journal-title":"Genes. Dev."},{"key":"10.1016\/j.tips.2017.06.003_bib0375","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/onc.2009.466","article-title":"Deficiency for the cysteine protease cathepsin L promotes tumor progression in mouse epidermis","volume":"29","author":"Dennemarker","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.tips.2017.06.003_bib0380","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1136\/gutjnl-2011-300850","article-title":"Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice","volume":"61","author":"Gopinathan","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.tips.2017.06.003_bib0385","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1101\/gad.1874010","article-title":"IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion","volume":"24","author":"Gocheva","year":"2010","journal-title":"Genes Dev."},{"key":"10.1016\/j.tips.2017.06.003_bib0390","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1101\/gad.249599.114","article-title":"Distinct functions of macrophage-derived and cancer cell-derived cathepsin Z combine to promote tumor malignancy via interactions with the extracellular matrix","volume":"28","author":"Akkari","year":"2014","journal-title":"Genes Dev."},{"key":"10.1016\/j.tips.2017.06.003_bib0395","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1002\/ijc.28238","article-title":"Cathepsin S from both tumor and tumor-associated cells promote cancer growth and neovascularization","volume":"133","author":"Small","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.tips.2017.06.003_bib0400","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1101\/gad.180331.111","article-title":"Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer","volume":"25","author":"Shree","year":"2011","journal-title":"Genes Dev."},{"key":"10.1016\/j.tips.2017.06.003_bib0405","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1158\/0008-5472.CAN-05-4463","article-title":"Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer","volume":"66","author":"Vasiljeva","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.tips.2017.06.003_bib0410","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ccell.2016.05.017","article-title":"The multifaceted role of perivascular macrophages in tumors","volume":"30","author":"Lewis","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tips.2017.06.003_bib0415","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000276564","article-title":"Interleukin-6 increases expression and secretion of cathepsin B by breast tumor-associated monocytes","volume":"25","author":"Mohamed","year":"2010","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.tips.2017.06.003_bib0420","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1186\/1471-2164-14-853","article-title":"Reprogramming of lysosomal gene expression by interleukin-4 and Stat6","volume":"14","author":"Brignull","year":"2013","journal-title":"BMC Genomics"},{"key":"10.1016\/j.tips.2017.06.003_bib0425","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.1158\/0008-5472.CAN-08-4539","article-title":"VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation","volume":"69","author":"Chang","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.tips.2017.06.003_bib0430","doi-asserted-by":"crossref","first-page":"6020","DOI":"10.1074\/jbc.M509134200","article-title":"Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors","volume":"281","author":"Wang","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0435","doi-asserted-by":"crossref","first-page":"18167","DOI":"10.1074\/jbc.M801327200","article-title":"Cathepsin L. 1 is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment","volume":"283","author":"Abboud-Jarrous","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0440","doi-asserted-by":"crossref","first-page":"37158","DOI":"10.1074\/jbc.M111.284869","article-title":"Cysteine cathepsins S and L modulate anti-angiogenic activities of human endostatin","volume":"286","author":"Veillard","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0445","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/ncb3011","article-title":"Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S","volume":"16","author":"Sevenich","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.tips.2017.06.003_bib0450","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nm.2999","article-title":"Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth","volume":"19","author":"Bruchard","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2017.06.003_bib0455","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/ni.1631","article-title":"Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization","volume":"9","author":"Hornung","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tips.2017.06.003_bib0460","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1073\/pnas.0804897106","article-title":"Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome","volume":"106","author":"Sharp","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2017.06.003_bib0465","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.tips.2017.06.003_bib0470","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.4049\/jimmunol.1500509","article-title":"Multiple cathepsins promote pro-IL-1beta synthesis and NLRP3-mediated IL-1beta activation","volume":"195","author":"Orlowski","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.tips.2017.06.003_bib0475","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1128\/IAI.00730-09","article-title":"CA-074Me protection against anthrax lethal toxin","volume":"77","author":"Newman","year":"2009","journal-title":"Infect. Immun."},{"key":"10.1016\/j.tips.2017.06.003_bib0480","doi-asserted-by":"crossref","first-page":"31736","DOI":"10.1074\/jbc.M114.609396","article-title":"A role for stefin B (cystatin B) in inflammation and endotoxemia","volume":"289","author":"Maher","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0485","doi-asserted-by":"crossref","DOI":"10.1189\/jlb.3HI0316-152R","article-title":"Multiple cathepsins promote inflammasome-independent, particle-induced cell death during NLRP3-dependent IL-1beta activation","author":"Orlowski","year":"2017","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.tips.2017.06.003_bib0490","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1093\/emboj\/20.17.4629","article-title":"Lysosomal cysteine proteases: facts and opportunities","volume":"20","author":"Turk","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.tips.2017.06.003_bib0495","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0167-4838(99)00263-0","article-title":"Lysosomal cysteine proteases: more than scavengers","volume":"1477","author":"Turk","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.tips.2017.06.003_bib0500","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0006-291X(67)80055-X","article-title":"On the size of the active site in proteases. I","volume":"27","author":"Schechter","year":"1967","journal-title":"Papain. Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tips.2017.06.003_bib0505","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1515\/bchm.1998.379.2.137","article-title":"Revised definition of substrate binding sites of papain-like cysteine proteases","volume":"379","author":"Turk","year":"1998","journal-title":"Biol. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0510","first-page":"1581","article-title":"Proteinases 1: lysosomal cysteine proteinases","volume":"2","author":"Kirschke","year":"1995","journal-title":"Protein Profile"},{"key":"10.1016\/j.tips.2017.06.003_bib0515","doi-asserted-by":"crossref","first-page":"12824","DOI":"10.1074\/jbc.M513331200","article-title":"Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities","volume":"281","author":"Choe","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0520","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1002\/pmic.201400460","article-title":"Fast profiling of protease specificity reveals similar substrate specificities for cathepsins K, L and S","volume":"15","author":"Vizovi\u0161ek","year":"2015","journal-title":"Proteomics"},{"key":"10.1016\/j.tips.2017.06.003_bib0525","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.15252\/embj.201796750","article-title":"Protease cleavage site fingerprinting by label-free in-gel degradomics reveals novel pH-dependent specificity switch of legumain","volume":"36","author":"Vidmar","year":"2017","journal-title":"EMBO J."},{"key":"10.1016\/j.tips.2017.06.003_bib0530","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/nmeth.2182","article-title":"Global identification of peptidase specificity by multiplex substrate profiling","volume":"9","author":"O\u2019Donoghue","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.tips.2017.06.003_bib0535","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1021\/pr200621z","article-title":"Proteomic identification of protease cleavage sites characterizes prime and non-prime specificity of cysteine cathepsins B, L, and S","volume":"10","author":"Biniossek","year":"2011","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.tips.2017.06.003_bib0540","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.4049\/jimmunol.180.5.2876","article-title":"Lysosomal cysteine and aspartic proteases are heterogeneously expressed and act redundantly to initiate human invariant chain degradation","volume":"180","author":"Costantino","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.tips.2017.06.003_bib0545","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1074\/jbc.M308347200","article-title":"Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of Bid by multiple papain-like lysosomal cathepsins","volume":"279","author":"Cirman","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0550","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.celrep.2016.06.086","article-title":"TAILS N-terminomics and proteomics show protein degradation dominates over proteolytic processing by cathepsins in pancreatic tumors","volume":"16","author":"Prudova","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.tips.2017.06.003_bib0555","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1107\/S0907444902021479","article-title":"Lysosomal cysteine proteases (cathepsins): promising drug targets","volume":"59","author":"Turk","year":"2003","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.tips.2017.06.003_bib0560","doi-asserted-by":"crossref","first-page":"14249","DOI":"10.1073\/pnas.94.26.14249","article-title":"Design of potent and selective human cathepsin K inhibitors that span the active site","volume":"94","author":"Thompson","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2017.06.003_bib0565","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nsb0297-105","article-title":"Crystal structure of human cathepsin K complexed with a potent inhibitor","volume":"4","author":"McGrath","year":"1997","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.tips.2017.06.003_bib0570","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1517\/13543776.2011.553800","article-title":"Cathepsin S inhibitors: 2004\u20132010","volume":"21","author":"Lee-Dutra","year":"2011","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.tips.2017.06.003_bib0575","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0079-6468(04)42006-2","article-title":"Cathepsin K inhibitors: their potential as anti-osteoporosis agents","volume":"42","author":"Deaton","year":"2004","journal-title":"Prog. Med. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0580","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.bmcl.2007.12.047","article-title":"The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K","volume":"18","author":"Gauthier","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tips.2017.06.003_bib0585","doi-asserted-by":"crossref","first-page":"6928","DOI":"10.1021\/acs.jmedchem.5b00746","article-title":"Development of N-(functionalized benzoyl)-homocycloleucyl-glycinonitriles as potent cathepsin K inhibitors","volume":"58","author":"Bori\u0161ek","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0590","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1042\/BCJ20160985","article-title":"Identification of mouse cathepsin K structural elements that regulate the potency of odanacatib","volume":"474","author":"Law","year":"2017","journal-title":"Biochem. J."},{"key":"10.1016\/j.tips.2017.06.003_bib0595","doi-asserted-by":"crossref","first-page":"6363","DOI":"10.1021\/jm3007257","article-title":"(1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole -2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis","volume":"55","author":"Dossetter","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0600","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.bmcl.2010.01.104","article-title":"Discovery and SAR of novel pyrazole-based thioethers as cathepsin S inhibitors. Part 2: modification of P3, P4, and P5 regions","volume":"20","author":"Wiener","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tips.2017.06.003_bib0605","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1016\/j.bmcl.2009.05.071","article-title":"Dipeptidyl nitrile inhibitors of cathepsin L","volume":"19","author":"Asaad","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tips.2017.06.003_bib0610","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1515\/BC.2009.065","article-title":"Subsite cooperativity in protease specificity","volume":"390","author":"Ng","year":"2009","journal-title":"Biol. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0615","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1515\/BC.2009.092","article-title":"Pharmacological inhibitors to identify roles of cathepsin K in cell-based studies: a comparison of available tools","volume":"390","author":"Desmarais","year":"2009","journal-title":"Biol. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0620","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1021\/jm000481x","article-title":"Azepanone-based inhibitors of human and rat cathepsin K","volume":"44","author":"Marquis","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0625","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1359\/jbmr.2001.16.10.1739","article-title":"Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate","volume":"16","author":"Stroup","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tips.2017.06.003_bib0630","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1007\/s00198-011-1529-x","article-title":"Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys","volume":"22","author":"Jerome","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.tips.2017.06.003_bib0635","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1021\/jm0504961","article-title":"Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity","volume":"48","author":"Falgueyret","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0640","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1124\/mol.107.039511","article-title":"Effect of cathepsin K inhibitor basicity on in vivo off-target activities","volume":"73","author":"Desmarais","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.tips.2017.06.003_bib0645","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/jbmr.2047","article-title":"Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study","volume":"29","author":"Eastell","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tips.2017.06.003_bib0650","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/jbmr.2080","article-title":"The effect of the cathepsin K inhibitor ONO-5334 on trabecular and cortical bone in postmenopausal osteoporosis: the OCEAN study","volume":"29","author":"Engelke","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tips.2017.06.003_bib0655","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1359\/jbmr.091035","article-title":"Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density","volume":"25","author":"Bone","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tips.2017.06.003_bib0660","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/1759720X15580903","article-title":"Odanacatib: a review of its potential in the management of osteoporosis in postmenopausal women","volume":"7","author":"Chapurlat","year":"2015","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.tips.2017.06.003_bib0665","doi-asserted-by":"crossref","DOI":"10.1038\/nrd.2016.207","article-title":"Merck & Co. drops osteoporosis drug odanacatib","volume":"15","author":"Mullard","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2017.06.003_bib0670","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00774-014-0609-3","article-title":"Efficacy and safety of odanacatib treatment for patients with osteoporosis: a meta-analysis","volume":"33","author":"Feng","year":"2015","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.tips.2017.06.003_bib0675","doi-asserted-by":"crossref","first-page":"A310","DOI":"10.1016\/j.joca.2015.02.561","article-title":"Inhibition of CTX-II release by cathepsin K inhibition in vivo but not in vitro suggests that anti-resorptive therapy protects cartilage","volume":"23","author":"Lindstrom","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.tips.2017.06.003_bib0680","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.bone.2012.03.025","article-title":"Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis","volume":"50","author":"Hayami","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.tips.2017.06.003_bib0685","doi-asserted-by":"crossref","first-page":"S454","DOI":"10.1016\/j.joca.2016.01.828","article-title":"The cathepsin K inhibitor L-006235 has analgesic and disease modifying properties in the MIA model of osteoarthritis","volume":"24","author":"Burston","year":"2016","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.tips.2017.06.003_bib0690","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.bbapap.2011.06.020","article-title":"Proteases involved in cartilage matrix degradation in osteoarthritis","volume":"1824","author":"Troeberg","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.tips.2017.06.003_bib0695","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s00223-002-2092-4","article-title":"Cathepsin K deficiency in pycnodysostosis results in accumulation of non-digested phagocytosed collagen in fibroblasts","volume":"73","author":"Everts","year":"2003","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.tips.2017.06.003_bib0700","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/S0002-9440(10)63777-7","article-title":"Pivotal role of cathepsin K in lung fibrosis","volume":"164","author":"Buhling","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.tips.2017.06.003_bib0705","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1172\/JCI15990","article-title":"Thyroid functions of mouse cathepsins B, K, and L","volume":"111","author":"Friedrichs","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2017.06.003_bib0710","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1042\/BJ20040864","article-title":"Cathepsin K: a cysteine protease with unique kinin-degrading properties","volume":"383","author":"Godat","year":"2004","journal-title":"Biochem. J."},{"key":"10.1016\/j.tips.2017.06.003_bib0715","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/jbm.b.33481","article-title":"Local co-delivery of rhBMP-2 and cathepsin K inhibitor L006235 in poly(d,l-lactide-co-glycolide) nanospheres","volume":"105","author":"Yu","year":"2017","journal-title":"J. Biomed. Mater. Res. B Appl. Biomater."},{"key":"10.1016\/j.tips.2017.06.003_bib0720","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1042\/BJ20140809","article-title":"Structural requirements for the collagenase and elastase activity of cathepsin K and its selective inhibition by an exosite inhibitor","volume":"465","author":"Sharma","year":"2015","journal-title":"Biochem. J."},{"key":"10.1016\/j.tips.2017.06.003_bib0725","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1038\/ncomms4287","article-title":"A novel allosteric mechanism in the cysteine peptidase cathepsin K discovered by computational methods","volume":"5","author":"Novinec","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2017.06.003_bib0730","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jaut.2011.01.003","article-title":"Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity","volume":"36","author":"Baugh","year":"2011","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.tips.2017.06.003_bib0735","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1165\/rcmb.2009-0392OC","article-title":"Genetic and pharmacological evaluation of cathepsin s in a mouse model of asthma","volume":"45","author":"Deschamps","year":"2011","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.tips.2017.06.003_bib0740","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.4049\/jimmunol.174.3.1729","article-title":"Cathepsin S is required for murine autoimmune myasthenia gravis pathogenesis","volume":"174","author":"Yang","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.tips.2017.06.003_bib0745","article-title":"Characterization of VBY-129, a cathepsin S inhibitor efficacious in a mouse model of psoriasis","volume":"129","author":"Holsinger","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.tips.2017.06.003_bib0750","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1002\/art.38633","article-title":"Tear cathepsin S as a candidate biomarker for Sjogren\u2019s syndrome","volume":"66","author":"Hamm-Alvarez","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.tips.2017.06.003_bib0755","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/annrheumdis-2013-203717","article-title":"Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4T cell and B cell priming","volume":"74","author":"Rupanagudi","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.tips.2017.06.003_bib0760","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1124\/jpet.116.232926","article-title":"Selective cathepsin S inhibition with MIV-247 attenuates mechanical allodynia and enhances the antiallodynic effects of gabapentin and pregabalin in a mouse model of neuropathic pain","volume":"358","author":"Hewitt","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tips.2017.06.003_bib0765","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1016\/j.bmcl.2008.08.067","article-title":"Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-cyanopyrimidines. Part 2","volume":"18","author":"Irie","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tips.2017.06.003_bib0770","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/bcp.12470","article-title":"Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects","volume":"78","author":"Payne","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.tips.2017.06.003_bib0775","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1517\/13543784.2015.1099627","article-title":"Discontinued neuropathic pain therapy between 2009-2015","volume":"24","author":"Knezevic","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.tips.2017.06.003_bib0780","doi-asserted-by":"crossref","first-page":"708","DOI":"10.2174\/156802610791113469","article-title":"Therapeutic utility and medicinal chemistry of cathepsin C inhibitors","volume":"10","author":"Guay","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0785","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1124\/mol.108.045682","article-title":"In vivo inhibition of serine protease processing requires a high fractional inhibition of cathepsin C","volume":"73","author":"Methot","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.tips.2017.06.003_bib0790","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1515\/BC.2008.115","article-title":"Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model","volume":"389","author":"Schurigt","year":"2008","journal-title":"Biol. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0795","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1158\/0008-5472.CAN-11-2759","article-title":"Cathepsin B inhibition limits bone metastasis in breast cancer","volume":"72","author":"Withana","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.tips.2017.06.003_bib0800","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nnano.2011.112","article-title":"Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment","volume":"6","author":"Mikhaylov","year":"2011","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.tips.2017.06.003_bib0805","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.biochi.2010.04.023","article-title":"Identification and preclinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model","volume":"92","author":"Elie","year":"2010","journal-title":"Biochimie"},{"key":"10.1016\/j.tips.2017.06.003_bib0810","doi-asserted-by":"crossref","first-page":"6066","DOI":"10.1038\/onc.2015.51","article-title":"A novel cysteine cathepsin inhibitor yields macrophage cell death and mammary tumor regression","volume":"34","author":"Salpeter","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.tips.2017.06.003_bib0815","doi-asserted-by":"crossref","first-page":"19027","DOI":"10.18632\/oncotarget.3699","article-title":"Nitroxoline impairs tumor progression in vitro and in vivo by regulating cathepsin B activity","volume":"6","author":"Mirkovic","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.tips.2017.06.003_bib0820","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12943-016-0513-7","article-title":"A bioavailable cathepsin S nitrile inhibitor abrogates tumor development","volume":"15","author":"Wilkinson","year":"2016","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tips.2017.06.003_bib0825","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10585-016-9790-1","article-title":"Cathepsin L in tumor angiogenesis and its therapeutic intervention by the small molecule inhibitor KGP94","volume":"33","author":"Sudhan","year":"2016","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.tips.2017.06.003_bib0830","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.celrep.2016.09.083","article-title":"Macrophage-induced lymphangiogenesis and metastasis following paclitaxel chemotherapy is regulated by VEGFR3","volume":"17","author":"Alishekevitz","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.tips.2017.06.003_bib0835","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.biochi.2011.08.017","article-title":"Inhibition of Cathepsin S by Fsn0503 enhances the efficacy of chemotherapy in colorectal carcinomas","volume":"94","author":"Burden","year":"2012","journal-title":"Biochimie"},{"key":"10.1016\/j.tips.2017.06.003_bib0840","doi-asserted-by":"crossref","first-page":"11175","DOI":"10.18632\/oncotarget.3579","article-title":"Inhibition of cathepsin proteases attenuates migration and sensitizes aggressive N-Myc amplified human neuroblastoma cells to doxorubicin","volume":"6","author":"Gangoda","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.tips.2017.06.003_bib0845","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1365-2249.2010.04220.x","article-title":"Beneficial effects of cathepsin inhibition to prevent chemotherapy-induced intestinal mucositis","volume":"162","author":"Alamir","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.tips.2017.06.003_bib0850","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1161\/STROKEAHA.115.011573","article-title":"Characterizing cathepsin activity and macrophage subtypes in excised human carotid plaques","volume":"47","author":"Abd-Elrahman","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.tips.2017.06.003_bib0855","doi-asserted-by":"crossref","first-page":"7669","DOI":"10.1002\/anie.201310979","article-title":"In vivo imaging of mouse tumors by a lipidated cathepsin S substrate","volume":"53","author":"Hu","year":"2014","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.tips.2017.06.003_bib0860","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2310\/7290.2014.00001","article-title":"In vivo molecular imaging of cathepsin and matrix metalloproteinase activity discriminates between arthritic and osteoarthritic processes in mice","volume":"13","author":"Vermeij","year":"2014","journal-title":"Mol. Imaging"},{"key":"10.1016\/j.tips.2017.06.003_bib0865","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.bmc.2010.10.028","article-title":"Functional in vivo imaging of cysteine cathepsin activity in murine model of inflammation","volume":"19","author":"Cagli\u010d","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0870","doi-asserted-by":"crossref","first-page":"19755","DOI":"10.1038\/srep19755","article-title":"Non-invasive imaging of idiopathic pulmonary fibrosis using cathepsin protease probes","volume":"6","author":"Withana","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2017.06.003_bib0875","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nchembio.2007.26","article-title":"Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes","volume":"3","author":"Blum","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.tips.2017.06.003_bib0880","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/anie.200702811","article-title":"Selective activity-based probes for cysteine cathepsins","volume":"47","author":"Watzke","year":"2008","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.tips.2017.06.003_bib0885","doi-asserted-by":"crossref","first-page":"14726","DOI":"10.1021\/ja4056068","article-title":"Improved quenched fluorescent probe for imaging of cysteine cathepsin activity","volume":"135","author":"Verdoes","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.tips.2017.06.003_bib0890","doi-asserted-by":"crossref","first-page":"320ra324","DOI":"10.1126\/scitranslmed.aad0293","article-title":"A mouse\u2013human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer","volume":"8","author":"Whitley","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tips.2017.06.003_bib0895","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s11999-012-2560-8","article-title":"A novel imaging system permits real-time in vivo tumor bed assessment after resection of naturally occurring sarcomas in dogs","volume":"471","author":"Eward","year":"2013","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.tips.2017.06.003_bib0900","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1002\/cncr.27458","article-title":"Intraoperative detection and removal of microscopic residual sarcoma using wide-field imaging","volume":"118","author":"Mito","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.tips.2017.06.003_bib0905","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.chembiol.2015.12.003","article-title":"A bright future for precision medicine: advances in fluorescent chemical probe design and their clinical application","volume":"23","author":"Garland","year":"2016","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.tips.2017.06.003_bib0910","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.2967\/jnumed.115.171553","article-title":"Dual-modality activity-based probes as molecular imaging agents for vascular inflammation","volume":"57","author":"Withana","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tips.2017.06.003_bib0915","doi-asserted-by":"crossref","first-page":"10077","DOI":"10.1002\/anie.201402305","article-title":"Selective targeting of tumor and stromal cells by a nanocarrier system displaying lipidated cathepsin B inhibitor","volume":"53","author":"Mikhaylov","year":"2014","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.tips.2017.06.003_bib0920","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1038\/srep06081","article-title":"In vivo magnetic resonance imaging of tumor protease activity","volume":"4","author":"Haris","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2017.06.003_bib0925","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.7150\/thno.19081","article-title":"Non-invasive in vivo imaging of tumour-associated cathepsin B by a highly selective inhibitory DARPin","volume":"7","author":"Kramer","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.tips.2017.06.003_bib0930","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nprot.2016.004","article-title":"Labeling of active proteases in fresh-frozen tissues by topical application of quenched activity-based probes","volume":"11","author":"Withana","year":"2016","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.tips.2017.06.003_bib0935","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd4519","article-title":"Principles in the design of ligand-targeted cancer therapeutics and imaging agents","volume":"14","author":"Srinivasarao","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2017.06.003_bib0940","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.addr.2015.12.020","article-title":"Proteases in cancer drug delivery","volume":"97","author":"Vandooren","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.tips.2017.06.003_bib0945","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2016.02.008","article-title":"New developments for antibody\u2013drug conjugate-based therapeutic approaches","volume":"40","author":"de Goeij","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.tips.2017.06.003_bib0950","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1021\/acs.bioconjchem.6b00337","article-title":"Novel phosphate modified cathepsin B linkers: improving aqueous solubility and enhancing payload scope of ADCs","volume":"27","author":"Kern","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.tips.2017.06.003_bib0955","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1007\/s11095-015-1657-7","article-title":"Current ADC linker chemistry","volume":"32","author":"Jain","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.tips.2017.06.003_bib0960","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/1535-7163.MCT-15-1004","article-title":"Molecular basis of valine-citrulline-PABC linker instability in site-specific ADCs and its mitigation by linker design","volume":"15","author":"Dorywalska","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tips.2017.06.003_bib0965","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1158\/1078-0432.CCR-11-0488","article-title":"Brentuximab vedotin (SGN-35)","volume":"17","author":"Katz","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2017.06.003_bib0970","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/ijc.30569","article-title":"Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix","volume":"140","author":"Gebleux","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.tips.2017.06.003_bib0975","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00280-006-0296-4","article-title":"In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases","volume":"59","author":"Shaffer","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.tips.2017.06.003_bib0980","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/JTO.0b013e3181753b4b","article-title":"Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer","volume":"3","author":"Langer","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tips.2017.06.003_bib0985","doi-asserted-by":"crossref","first-page":"847","DOI":"10.7150\/thno.10854","article-title":"Photodynamic quenched cathepsin activity based probes for cancer detection and macrophage targeted therapy","volume":"5","author":"Ben-Nun","year":"2015","journal-title":"Theranostics"},{"key":"10.1016\/j.tips.2017.06.003_bib0990","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1161\/ATVBAHA.113.301290","article-title":"Photodynamic therapy using a protease-mediated theranostic agent reduces cathepsin-B activity in mouse atheromata in vivo","volume":"33","author":"Shon","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.tips.2017.06.003_bib0995","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1002\/j.1460-2075.1991.tb07771.x","article-title":"The refined 2.15\u00c5 X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity","volume":"10","author":"Musil","year":"1991","journal-title":"EMBO J."},{"key":"10.1016\/j.tips.2017.06.003_bib1000","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/emboj\/18.4.793","article-title":"Crystal structure of MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S","volume":"18","author":"Guncar","year":"1999","journal-title":"EMBO J."},{"key":"10.1016\/j.tips.2017.06.003_bib1005","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1093\/emboj\/20.23.6570","article-title":"Structure of human dipeptidyl peptidase I (cathepsinC): exclusion domain added to an endopeptidase framework creates the machine for activation of granular serine proteases","volume":"20","author":"Turk","year":"2001","journal-title":"EMBO J."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614717301219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614717301219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T02:07:59Z","timestamp":1719281279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614717301219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":201,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0165614717301219"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2017.06.003","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Future of Cysteine Cathepsins in Disease Management","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2017.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}